QDEL vs TRIB
QuidelOrtho Corp. and Trinity Biotech PLC, side by side — 5 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | QDEL | TRIB |
|---|---|---|
| Revenue | $2.7B | $61.6M |
| Net income | $-1.1B | $-31.8M |
| Gross margin | — | 34.8% |
| Net margin | −41.5% | −51.6% |
| Return on equity | −46.1% | — |
| Diluted EPS | −$16.69 | — |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | $-83.0M | $-4.6M |
| Equity | $1.9B | — |
| Net debt / equity | 1.41× | — |
| Current ratio | 1.50× | 1.28× |
| Revenue CAGR 5y | 10.4% | −7.4% |
| Profit CAGR 5y | — | — |
QDEL bills 44.4× the revenue of TRIB, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
5 years side by side
| Fiscal year | QDEL | TRIB |
|---|---|---|
| FY2024 | $2.8B | $61.6M |
| FY2023 | $3.0B | $56.8M |
| FY2022 | $3.3B | $62.5M |
| FY2021 | $1.7B | $81.1M |
| FY2020 | $1.7B | $102.0M |
Net income by year
Bottom line
| Fiscal year | QDEL | TRIB |
|---|---|---|
| FY2024 | $-2.1B | $-31.8M |
| FY2023 | $-10.1M | $-24.0M |
| FY2022 | $548.7M | $-41.0M |
| FY2021 | $704.2M | $875,000 |
| FY2020 | $810.3M | $-6.4M |
Advertisement
AdSense · Rectangle 336×280
More in this industry